Table 2 Patient demographic characteristics
From: Content validation of the SF-36v2® health survey with AL amyloidosis patients
Concept Elicitation | Cognitive Debriefing | |
|---|---|---|
Demographic Information | Mean (Range), years | |
Age | 57.2 (41–76) | 63.30 (39–74) |
Time since diagnosis | 2.3 (0.33–8) | 4.18 (0.50–18) |
Time from first symptom to diagnosis | 2 (0.25–4) | – |
N (%) | ||
Gender | ||
Male | 6 (60) | 5 (50) |
Female | 4 (40) | 5 (50) |
Region of U.S. Residence | ||
South | 4 (40) | 0 (0) |
Midwest | 3 (30) | 0 (0) |
East Coast | 2 (20) | 10 (100) |
West Coast | 1 (10) | 0 (0) |
Education | ||
Less than Bachelor’s degree | 4 (40) | 5 (50) |
Bachelor’s degree | 3 (30) | 2 (20) |
Post-graduate | 3 (30) | 3 (30) |
Multiple Organ Involvement | ||
Yes | 5 (50) | 4 (40) |
No | 5 (50) | 6 (60) |
Organs Affecteda | ||
Heart | 6 (60) | 5 (50) |
Kidney | 5 (50) | 6 (60) |
Gastrointestinal Tract | 3 (30) | 0 (0) |
Nervous System | 2 (20) | 1 (10) |
Liver | 0 (0) | 1 (10) |
Bladder | 0 (0) | 1 (10) |
Remission Status | ||
Full Remission | 5 (50) | 2 (20) |
Partial Remission | 1 (10) | 3 (30) |
Not in Remission | 4 (40) | 4 (40) |
Unsure | 0 (0) | 1 (10) |
Current Treatmenta | ||
Bortezomib (Velcade) | 4 (40) | – |
Dexamethasone | 3 (30) | – |
Doxycycline | 2 (20) | – |
Lenalidomide (Revlimid) | 2 (20) | – |
Other | 2 (20) | – |